HIT

Price Chart

Key Facts

• Received Nasdaq deficiency letter on October 14, 2026 for non-compliance with independent director and audit committee rules (5605(b)(1) and 5605(c)(2)(A)) after director resignation on August 10, 2026
• Board has only 2 of 4 independent directors; Audit Committee has only 2 members instead of required 3
• Cure period for governance deficiency runs until earlier of next annual meeting or August 10, 2027 (or February 8, 2027 if annual meeting held before that date)
• Received separate Nasdaq deficiency letter on October 12, 2026 for bid price below $1.00 for 30 consecutive business days
• 180-day compliance period for bid price runs through April 12, 2027; reverse stock split must be completed 10 business days before deadline
• Annual meeting scheduled for November 10, 2026 to elect new independent director
• S-3/A filed October 9, 2026 registers up to 34,224,247 shares for resale by Yorkville under toxic SEPA with convertible notes and equity line

Financial Impact

Potential delisting from Nasdaq would severely reduce institutional ownership and liquidity; S-3/A registers up to 34.2M shares for resale by Yorkville under a SEPA facility with up to $14.25M in convertible notes and $20M equity line

Risk Factors

• Failure to elect independent director at November 10 annual meeting would accelerate governance cure deadline to February 8, 2027
• Stock price may not recover to $1.00 within 180 days given dilutive SEPA facility and Yorkville selling pressure
• Reverse stock split, if needed, could further pressure the stock and may not be completed by the April 12, 2027 deadline
• Yorkville SEPA allows issuance of up to 34.2M shares at 97% of lowest VWAP, creating continuous downward pressure
• If delisted, stock would move to OTC markets with severely reduced liquidity and institutional ownership

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

US Market Status